TY - JOUR
T1 - Biological therapies for the treatment of Behçet’s disease-related uveitis beyond TNF-alpha blockade
T2 - a narrative review
AU - Sota, Jurgen
AU - Rigante, Donato
AU - Lopalco, Giuseppe
AU - Frediani, Bruno
AU - Franceschini, Rossella
AU - Galeazzi, Mauro
AU - Iannone, Florenzo
AU - Tosi, Gian Marco
AU - Fabiani, Claudia
AU - Cantarini, Luca
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Intraocular inflammation is one of the more relevant complications of Behçet’s disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.
AB - Intraocular inflammation is one of the more relevant complications of Behçet’s disease (BD), which tends to respond poorly to different medications. The ocular histopathologic changes are basically identical to those occurring in other organs and consist in a necrotizing leukocytoclastic obliterative vasculitis, which is probably immune complex-mediated and affects both arteries and veins of all sizes. There are growing evidences showing the potential role of biologic agents other than anti-tumor necrosis factor (TNF)-α agents in the management of ocular-BD, which have been collected in this review, including interleukin-1 and interleukin-6 blockade, secukinumab, ustekinumab, daclizumab, rituximab, and alemtuzumab. Further large studies are needed to fully elucidate and establish the clinical efficacy of these different tools in the refractory ocular manifestations of BD.
KW - Behçet’s disease
KW - Biologics
KW - Eye disease
KW - Treatment
KW - Uveitis
UR - http://www.scopus.com/inward/record.url?scp=85026907559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026907559&partnerID=8YFLogxK
U2 - 10.1007/s00296-017-3775-5
DO - 10.1007/s00296-017-3775-5
M3 - Review article
AN - SCOPUS:85026907559
VL - 38
SP - 25
EP - 35
JO - Rheumatology International
JF - Rheumatology International
SN - 0172-8172
IS - 1
ER -